Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pancreatic nerve electrostimulation inhibits recent-onset autoimmune diabetes

This article has been updated

Abstract

Vagus nerve stimulation can ameliorate autoimmune diseases such as rheumatoid arthritis by modulation of the immune system. Its efficacy for the treatment of type 1 diabetes has not been explored, in part because the nerves projecting to the pancreatic lymph nodes (pLNs) in mice are unmapped. Here, we map the nerve projecting to the pancreas and pLNs in mice and use a minimally invasive surgical procedure to implant micro-cuff electrodes onto the nerve. Pancreatic nerve electrical stimulation (PNES) resulted in β-adrenergic receptor-mediated-accumulation of B and T cells in pLNs and reduced production of pro-inflammatory cytokines following lipopolysaccharide stimulation. Autoreactive T cells showed reduced proliferation in pLNs of mice receiving PNES as compared to sham controls. In a spontaneous mouse model of autoimmune diabetes, PNES inhibited disease progression in diabetic mice.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Pancreatic nerve electrophysiological and functional characterization.
Fig. 2: Impact of PNES on immune cell number, cytokine production and T cell proliferation in pLNs.
Fig. 3: Impact of PNES on glycemia and insulitis in NOD mice.

Data availability

Datasets that support the findings of this study are available from the corresponding author upon reasonable request.

Change history

  • 19 February 2020

    In the supplementary information originally posted for this article, characters were corrupted in the figure lettering. The error has been corrected online.

References

  1. 1.

    Padro, C. J. & Sanders, V. M. Neuroendocrine regulation of inflammation. Semin. Immunol.26, 357–368 (2014).

    CAS  Article  Google Scholar 

  2. 2.

    Koopman, F. A. et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc. Natl Acad. Sci. USA113, 8284–8289 (2016).

    CAS  Article  Google Scholar 

  3. 3.

    Bonaz, B. et al. Chronic vagus nerve stimulation in Crohn’s disease: a 6-month follow-up pilot study. Neurogastroenterol. Motil.28, 948–953 (2016).

    CAS  Article  Google Scholar 

  4. 4.

    Herold, K. C. Restoring immune balance in type 1 diabetes. Lancet Diabetes Endocrinol.1, 261–263 (2013).

    Article  Google Scholar 

  5. 5.

    Coppieters, K. & von Herrath, M. The development of immunotherapy strategies for the treatment of type 1 diabetes. Front. Med.5, 283 (2018).

    Article  Google Scholar 

  6. 6.

    Duclaux, R., Mei, N. & Ranieri, F. Conduction velocity along the afferent vagal dendrites: a new type of fibre. J. Physiol.260, 487–495 (1976).

    CAS  Article  Google Scholar 

  7. 7.

    Nakai, A., Hayano, Y., Furuta, F., Noda, M. & Suzuki, K. Control of lymphocyte egress from lymph nodes through β2-adrenergic receptors. J. Exp. Med.211, 2583–2598 (2014).

    CAS  Article  Google Scholar 

  8. 8.

    Faustman, D. L. et al. TNF, TNF inducers, and TNFR2 agonists: a new path to type 1 diabetes treatment. Diabetes Metab. Res. Rev. https://doi.org/10.1002/dmrr.2941 (2018).

    Article  Google Scholar 

  9. 9.

    Mandrup-Poulsen, T. Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes. Rev. Diabet. Stud. RDS9, 338–347 (2012).

    Article  Google Scholar 

  10. 10.

    Chen, Y.-L. et al. Correlation between serum interleukin-6 level and type 1 diabetes mellitus: a systematic review and meta-analysis. Cytokine94, 14–20 (2017).

    CAS  Article  Google Scholar 

  11. 11.

    Kurts, C., Heath, W. R., Kosaka, H., Miller, J. F. & Carbone, F. R. The peripheral deletion of autoreactive CD8+ T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). J. Exp. Med.188, 415–420 (1998).

    CAS  Article  Google Scholar 

  12. 12.

    Amrani, A. et al. Perforin-independent beta-cell destruction by diabetogenic CD8(+) T lymphocytes in transgenic nonobese diabetic mice. J. Clin. Invest.103, 1201–1209 (1999).

    CAS  Article  Google Scholar 

  13. 13.

    Christianson, S. W., Shultz, L. D. & Leiter, E. H. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes42, 44–55 (1993).

    CAS  Article  Google Scholar 

  14. 14.

    Hervé, J. et al. β2-Adrenoreceptor agonist inhibits antigen cross-presentation by dendritic cells. J. Immunol.190, 3163–3171 (2013).

    Article  Google Scholar 

  15. 15.

    Hogquist, K. A. et al. T cell receptor antagonist peptides induce positive selection. Cell76, 17–27 (1994).

    CAS  Article  Google Scholar 

  16. 16.

    Kurts, C., Miller, J. F., Subramaniam, R. M., Carbone, F. R. & Heath, W. R. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J. Exp. Med.188, 409–414 (1998).

    CAS  Article  Google Scholar 

  17. 17.

    Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci.13, 133–140 (2010).

    CAS  Article  Google Scholar 

  18. 18.

    Savitt, J. M., Jang, S. S., Mu, W., Dawson, V. L. & Dawson, T. M. Bcl-x is required for proper development of the mouse substantia nigra. J. Neurosci.25, 6721–6728 (2005).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This work was funded by a collaborative research grant from GlaxoSmithKline Bioelectronics R&D to P.B. This work was also supported by the LABEX SIGNALIFE (no. ANR-11-LABX-0028-01) and the FHU Oncoage.

Author information

Affiliations

Authors

Contributions

P.B. conceived the study. M.G., T.S. and P.B. designed experiments. M.G., F.C., T.S., A.G., C.P., E.M., D.D., R.B., S.A., S.H-A., S.J.L. and P.B. performed experiments. M.G., F.C., T.S., A.G., A.S., N.G. and P.B. interpreted the data. S.J.L. helped to identify the location of the pancreatic nerve in mice. J.-L.D. provided one of the external stimulators used in this study. P.B. wrote the manuscript and N.G. edited the manuscript. All the authors read and approved the final manuscript.

Corresponding author

Correspondence to Philippe Blancou.

Ethics declarations

Competing interests

A patent application is pending.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Material

Supplementary Figs. 1–14.

Reporting Summary

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Guyot, M., Simon, T., Ceppo, F. et al. Pancreatic nerve electrostimulation inhibits recent-onset autoimmune diabetes. Nat Biotechnol 37, 1446–1451 (2019). https://doi.org/10.1038/s41587-019-0295-8

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing